The Third Field

Cases from the record · 1960 – 1962

Frances Kelsey at the FDA

One reviewer kept asking for the evidence

A newly arrived FDA medical officer found the application for a popular European sedative incomplete, and kept asking for evidence for eighteen months. That application was withdrawn without approval.

Process lens Proposals → Decide

~18 monthsfrom the application in September 1960 to its withdrawal in March 1962
60 daysthe review period under the rules then in force; an incomplete application restarted the clock (FDA)
1962new law: drugs must show “substantial evidence” of effectiveness from well-controlled investigations

What happened

In September 1960 an American drug company applied to the FDA to sell thalidomide, a sedative already sold in Europe, under the name Kevadon. The application was assigned to Dr. Frances Oldham Kelsey, a medical officer who had joined the agency about a month before.

She and her colleagues found the safety data inadequate and asked for more. The company pressed for a decision. In late 1961 doctors in Germany linked the drug to severe birth defects, and it was withdrawn there. The company withdrew its American application in March 1962. That August the President honored her for federal civilian service, and in October Congress strengthened the drug law.

  1. The application for Kevadon reaches the FDA and is assigned to Dr. Kelsey.

  2. The reviewers judge the application incomplete and ask for more data.

  3. A letter in the British Medical Journal reports nerve damage in long-term users; more information is requested.

  4. The company presses for a decision and raises its concerns with her superiors.

  5. Doctors in Germany link the drug to birth defects; it is withdrawn there.

  6. The company withdraws its American application.

  7. Dr. Kelsey receives the President’s Award for Distinguished Federal Civilian Service; the Kefauver-Harris Amendments become law.

What the record shows

  1. 01

    The rules favored speed.

    The FDA then had 60 days to act on an application. Declaring it incomplete was the reviewer’s way to keep asking, and each resubmission restarted the clock.

  2. 02

    The objections were about evidence.

    The FDA’s own account lists them: toxicity studies that were too short, inadequate data on how the drug was absorbed and excreted, and clinical reports that read like testimonials. It describes a reviewer who “adamantly insisted on scientifically reliable evidence.”

  3. 03

    A report from outside changed the question.

    A short letter in a British journal described nerve damage in long-term users. It became part of the record of the review and a reason to ask for more.

  4. 04

    Pressure did not move the record.

    The company called, visited and complained to her superiors. In 1962 a member of Congress described her as “backed by her supervisors.”

  5. 05

    The recognition named the judgment.

    The 1962 citation credited “her exceptional judgment in evaluating a new drug for safety for human use.”

Our reading · Proposals → Decide

One perspective that holds to the evidence needs a place where a deadline or a phone call cannot wear it down. The requests were written, specific and part of the record, and the decision could not be settled until they were answered.

Context and limits

This was a team review backed by her supervisors, not one person’s veto, and the link to birth defects came from doctors abroad in 1961. The original sedative application was not approved, although the drug reached American doctors for investigational use. Thalidomide was later approved in the United States for other indications, beginning in 1998.

From the record to a design question

Can an unanswered evidence question remain open when everyone wants the decision closed?

What this asks of the process

Treat “not yet” as a meaningful state. Name the missing evidence and the authority needed to evaluate it. Other work may advance while that question remains unresolved.

What we do not conclude

Keeping a question visible is not equivalent to exercising regulatory authority. This case illustrates evidence-based review supported by a team and its supervisors, not a product outcome.

This is our design inference from the case. The case does not test Sikizana. See the research that informs the sequence

Sources

  1. FDA History Office, Frances Oldham Kelsey: medical reviewer famous for averting a public health tragedy
  2. FDA, The History of Drug Regulation in the United States (2006)
  3. FDA, orphan drug approval record for thalidomide (16 July 1998)
  4. Remarks upon presenting the President’s Awards for Distinguished Federal Civilian Service (7 August 1962)
  5. Drug Amendments of 1962, Public Law 87-781, 76 Stat. 780
  6. Kelsey, F. O. (1965). Problems raised for the FDA by the occurrence of thalidomide embryopathy in Germany, 1960–1961. American Journal of Public Health, 55(5), 703–707
  7. Remarks of Rep. John E. Fogarty (31 October 1962), Providence College Digital Commons

Based on the linked official record, participants’ accounts and original research. Retrospective accounts and investigations have different limits; they are not controlled tests of a decision method. No organization named here is presented as a customer, partner or endorser of The Third Field.